New insider activity at Amneal Pharmaceuticals ( (AMRX) ) has taken place on March 8, 2025.
Recent insider transactions at Amneal Pharmaceuticals reveal significant stock sales by key executives and directors. EVP and CLO Jason B. Daly sold 90,000 shares for $792,159, while Director Emily Peterson parted with 80,000 shares, amounting to $712,000. Additionally, EVP Andrew S. Boyer sold 125,000 shares for a total of $1,111,250. Director Tasos Konidaris also sold 100,000 shares, netting $891,000. These transactions highlight a substantial divestment by the company’s leadership.
Recent Updates on AMRX stock
In the last 24 hours, Amneal Pharmaceuticals has seen significant developments that have influenced its stock performance. The company announced that the FDA has accepted its Biologics Licensing Application for two proposed denosumab biosimilars, with a target action date in the fourth quarter of 2025. This positions Amneal to potentially expand its biosimilar portfolio significantly by 2027. Additionally, Barclays raised its price target for Amneal Pharmaceuticals, citing the company’s strong Q4 performance, robust 2025 guidance, and successful deleveraging efforts as key factors. Amneal reported a substantial 18% increase in Q4 2024 net revenue, driven by new product launches and double-digit growth across its business segments. Despite a GAAP net loss, the company achieved an adjusted net income, reflecting its strategic growth initiatives. Looking forward, Amneal has provided optimistic financial guidance for 2025, projecting continued revenue growth and further expansion into high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies.
More about Amneal Pharmaceuticals
YTD Price Performance: 12.89%
Average Trading Volume: 1,295,452
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.78B